Erbb Receptors: from Oncogenes to Targeted Cancer Therapies.
From: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6082, USA.
The Journal of clinical investigation
- Publish Date: Aug 2007
- ISSN: 0021-9738
- Volume: 117
- Issue: 8
- Pages: 2051-8
- Medium: Print
- Language: English
- Citation (JAMA): Zhang Hongtao, Berezov Alan, Wang Qiang, et al. Erbb Receptors: from Oncogenes to Targeted Cancer Therapies.. J. Clin. Invest. Aug 2007;117:2051-8
Abstract
Understanding the genetic origin of cancer at the molecular level has facilitated the development of novel targeted therapies. Aberrant activation of the ErbB family of receptors is implicated in many human cancers and is already the target of several anticancer therapeutics. The use of mAbs specific for the extracellular domain of ErbB receptors was the first implementation of rational targeted therapy. The cytoplasmic tyrosine kinase domain is also a preferred target for small compounds that inhibit the kinase activity of these receptors. However, current therapy has not yet been optimized, allowing for opportunities for optimization of the next generation of targeted therapy, particularly with regards to inhibiting heteromeric ErbB family receptor complexes.
Mesh Headings (Keywords): Animals, Antibodies, Monoclonal, Drug Delivery Systems, Enzyme Activation, Enzyme Inhibitors, Humans, Neoplasms, Protein Structure, Tertiary, Receptor, Epidermal Growth Factor
Check for Full Text / PubMed Unique Identifier (PMID): 17671639
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.